dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Shitara, Kohei |
dc.contributor.author | Zaanan, Aziz |
dc.contributor.author | Doi, Toshihiko |
dc.contributor.author | Lorenzen, S. |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Alsina Maqueda, Maria |
dc.date.accessioned | 2022-04-06T06:50:47Z |
dc.date.available | 2022-04-06T06:50:47Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Tabernero J, Shitara K, Zaanan A, Doi T, Lorenzen S, Van Cutsem E, et al. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open. 2021 Aug;6(4):100200. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7307 |
dc.description | Càncer gàstric metastàtic; Supervivència global; Trifluridina/tipiracil |
dc.description.sponsorship | The TAGS study was funded by Taiho Oncology and Taiho Pharmaceutical (no grant number). This exploratory subgroup analysis was funded by Servier (no grant number). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Estómac - Càncer - Tractament |
dc.subject | Metàstasi |
dc.subject.mesh | Stomach Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neoplasm Metastasis |
dc.title | Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100200 |
dc.subject.decs | neoplasias gástricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | metástasis neoplásica |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100200 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain. [Shitara K] Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. [Zaanan A] Department of Gastrointestinal Oncology, European Georges Pompidou Hospital, AP-HP Centre, University of Paris, Paris, France. [Doi T] Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan. [Lorenzen S] Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum Rechts der Isar, Technische Universitaet München, München, Germany. [Van Cutsem E] Department of Gastroenterology and Digestive Oncology, University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium. [Alsina M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34175675 |
dc.identifier.wos | 000703610200021 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |